Progyny, Inc. (PGNY) Stock
PGNY has an Alpha Score of 52 out of 100 (weak), computed on Oct 29, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 5 trades in PGNY since 2020: 4 purchases and 1 sale, most recently Josh Gottheimer (sale, Dec 6, 2024). 7 of the hedge funds AlphaScala tracks reported PGNY in 13F filings for the quarter ended Sep 30, 2026; the largest reported position is Citadel's at $51.48M. Company insiders reported 0 open-market buys and 4 sales on SEC Form 4 in the 90 days to Nov 3, 2026. Its trailing P/E ratio is 27.2 and its net margin 6.0% (key statistics as of Oct 29, 2026).
What is PGNY's Alpha Score?
How it works →Alpha Score of 52 reflects moderate overall profile with moderate momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 29, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Progyny, Inc. (PGNY)?
Most recent: Josh Gottheimer (sale, Dec 6, 2024); records start May 21, 2020.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Josh Gottheimer D-NJ · House | 2024-12-06 | sale | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-07-30 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-06-30 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-06-01 | purchase | $1k – $15k |
| Gil Cisneros D-CA · House | 2020-05-21 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026.
See all PGNY political trades →Which hedge funds own PGNY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 1.79M | $51.48M | NEW |
| Millennium Management Israel Englander | 440K | $12.67M | +489% |
| Renaissance Technologies Jim Simons (founder) | 425K | $12.24M | -48% |
| Marshall Wace | 344K | $9.92M | -28% |
| Hussman Investment Trust John Hussman | 63K | $1.59M | NEW |
| Bridgewater Associates Ray Dalio | 52K | $1.49M | NEW |
| D.E. Shaw David Shaw | 18K | $525.8K | -85% |
13F holdings as of Sep 30, 2026
Explore all tracked funds →Are Progyny, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 14, 26 | Cummings Melissa B | Chief Operating Officer | SELL | 1.9K | $53K |
| Sep 23, 26 | Swartz Allison | EVP, GC | SELL | 3.9K | $102K |
| Sep 10, 26 | Gordon Kevin K | Director | SELL | 11.5K | $312K |
| Sep 10, 26 | Gordon Kevin K | Director | SELL | 11.5K | $321K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are PGNY's key statistics?
Key statistics as of Oct 29, 2026
How does PGNY's valuation compare with the Healthcare sector?
| Metric | PGNY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 27.2 | 27.0 | 102 |
| Net margin | 6.00% | 4.64% | 150 |
| Return on equity | 15.98% | 6.41% | 169 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
PGNY price chart
Powered by TradingViewWhat does Progyny, Inc. do?
Progyny Inc. is a leading provider of comprehensive fertility, family building, and women's health benefits solutions designed for employers, health plans, and benefit purchasers. Its data-driven model delivers cohesive care from preconception through fertility, pregnancy, postpartum, return-to-work support, menopause, and midlife, empowering members with personalized clinical coaching, high-touch concierge services, and seamless access to in-person and virtual care. Progyny manages an actively managed network of top-tier women's health providers, including fertility specialists, reproductive endocrinologists, doulas, lactation consultants, and menopause experts, all NCQA-accredited in credentialing. The platform supports diverse paths to parenthood, such as adoption, surrogacy, and assisted reproductive technologies, alongside integrated prescription management and digital tools for global workforces. By focusing on superior clinical outcomes, member experiences, and cost efficiencies, Progyny integrates flexibly into existing benefit ecosystems across numerous industries, fostering healthier journeys at life's key milestones.